Cargando…

Cell-based therapeutic strategies for multiple sclerosis

The availability of multiple disease-modifying medications with regulatory approval to treat multiple sclerosis illustrates the substantial progress made in therapy of the disease. However, all are only partially effective in preventing inflammatory tissue damage in the central nervous system and no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scolding, Neil J, Pasquini, Marcelo, Reingold, Stephen C, Cohen, Jeffrey A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841198/ https://www.ncbi.nlm.nih.gov/pubmed/29053779 http://dx.doi.org/10.1093/brain/awx154

Ejemplares similares

Vision and vision-related outcome measures in multiple sclerosis
por: Balcer, Laura J., et al.
Publicado: (2015)

Risk evaluation and monitoring in multiple sclerosis therapeutics
por: Clanet, Michel C, et al.
Publicado: (2014)

Mechanisms of Oxidative Damage in Multiple Sclerosis and a Cell Therapy Approach to Treatment
por: Witherick, Jonathan, et al.
Publicado: (2010)

Microglia depletion as a therapeutic strategy: friend or foe in multiple sclerosis models?
por: Wies Mancini, Victoria Sofia Berenice, et al.
Publicado: (2022)

A systematic review of the incidence and prevalence of cancer in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

The challenge of comorbidity in clinical trials for multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Purkinje Cell Pathology and Loss in Multiple Sclerosis Cerebellum
por: Redondo, Juliana, et al.
Publicado: (2014)

Dysregulation of Mesenchymal Stromal Cell Antioxidant Responses in Progressive Multiple Sclerosis
por: Redondo, Juliana, et al.
Publicado: (2018)

The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Recommendations for observational studies of comorbidity in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Pregnancy, sex and hormonal factors in multiple sclerosis
por: Miller, David H, et al.
Publicado: (2014)

A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment
por: Cohen, Jeffrey A, et al.
Publicado: (2019)

Viral etiology of multiple sclerosis: where does the truth lie?
por: Waksman, Byron H., et al.
Publicado: (1986)

Galectin-3 prospects as a therapeutic agent for multiple sclerosis
por: Thomas, Laura, et al.
Publicado: (2019)

Multiple Sclerosis: Therapeutic Strategies on the Horizon
por: Talanki Manjunatha, Ramya, et al.
Publicado: (2022)

Exosomes and Biomaterials: In Search of a New Therapeutic Strategy for Multiple Sclerosis
por: Ojeda-Hernández, Doddy Denise, et al.
Publicado: (2022)

Current Status of the Immunomodulation and Immunomediated Therapeutic Strategies for Multiple Sclerosis
por: Chen, Shyi-Jou, et al.
Publicado: (2012)

Reduced neuroprotective potential of the mesenchymal stromal cell secretome with ex vivo expansion, age and progressive multiple sclerosis
por: Sarkar, Pamela, et al.
Publicado: (2018)

Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis
por: Tan, Yossan-Var, et al.
Publicado: (2011)

Cell fusion in the brain: two cells forward, one cell back
por: Kemp, Kevin, et al.
Publicado: (2014)

Novel Insights and Therapeutics in Multiple Sclerosis
por: Wagner, Catriona A., et al.
Publicado: (2015)

Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in vitro mesenchymal stromal cell-mediated neuroprotection
por: Sarkar, Pamela, et al.
Publicado: (2021)

Differential diagnosis of suspected multiple sclerosis: a consensus approach
por: Miller, DH, et al.
Publicado: (2008)

The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic
por: Azimzadeh, Maryam, et al.
Publicado: (2021)

Experimental and Therapeutic Opportunities for Stem Cells in Multiple Sclerosis
por: Patani, Rickie, et al.
Publicado: (2012)

Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies
por: Sundaram, Gayathri, et al.
Publicado: (2014)

KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis
por: Hares, Kelly, et al.
Publicado: (2021)

Defining the clinical course of multiple sclerosis: The 2013 revisions
por: Lublin, Fred D., et al.
Publicado: (2014)

The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue
por: Veauthier, Christian, et al.
Publicado: (2016)

Novel Therapeutic Strategies in the Treatment of Systemic Sclerosis
por: Gumkowska-Sroka, Olga, et al.
Publicado: (2023)

Should mast cells be considered therapeutic targets in multiple sclerosis?
por: Pinke, Karen Henriette, et al.
Publicado: (2020)

Nodding syndrome: a concise review
por: Olum, Sam, et al.
Publicado: (2020)

Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies
por: Fitzner, Dirk, et al.
Publicado: (2010)

Kynurenines in the Pathogenesis of Multiple Sclerosis: Therapeutic Perspectives
por: Biernacki, Tamás, et al.
Publicado: (2020)

Oligodendrocyte Development and Regenerative Therapeutics in Multiple Sclerosis
por: Gacem, Nadjet, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g15cjc6uf19mkvu7hev4t5877q